Online inquiry

IVTScrip™ mRNA-Anti-ADCYAP1R1, AMG-301(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2802MR)

This product GTTS-WQ2802MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets ADCYAP1R1 gene. The antibody can be applied in Migraine research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001118.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 117
UniProt ID P41586
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ADCYAP1R1, AMG-301(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ2802MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6048MR IVTScrip™ mRNA-Anti-IL6, CNTO 136(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CNTO 136
GTTS-WQ341MR IVTScrip™ mRNA-Anti-CD27, 1F5(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA 1F5
GTTS-WQ8956MR IVTScrip™ mRNA-Anti-IL1RL2, IL2 fused to diphteria toxin(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA IL2 fused to diphteria toxin
GTTS-WQ3930MR IVTScrip™ mRNA-Anti-CTLA4, BCD-145(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BCD-145
GTTS-WQ4887MR IVTScrip™ mRNA-Anti-ACVR2, BYM338(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BYM338
GTTS-WQ8588MR IVTScrip™ mRNA-Anti-FOLH1, HuJ591-DOTA(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA HuJ591-DOTA
GTTS-WQ10782MR IVTScrip™ mRNA-Anti-FGFR4, M-70(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA M-70
GTTS-WQ10213MR IVTScrip™ mRNA-Anti-RHD, LFB-R593(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA LFB-R593
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW